Semax
Last reviewed 2026-10-30
Our read Opinion
Russian clinical studies report recovery signals, but do not establish cognitive enhancement in healthy people. FDA lists withdrawn nominations with unresolved safety concerns; removal is not clearance.
- Type
- Approved outside US
- Regulatory status
- Reported Russian approval; not FDA-approved
- Compounding status
- Off Category 2, review pending
- FDA-approved indications
- None
- Evidence level
- Small/early human studies
- Routes studied
- Nasal
- WADA
- Verify
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to support cognition
An ACTH-fragment analogue studied for neuroprotective effects and modulation of neurotrophin signaling, including BDNF. Clinical mechanism remains incompletely established.
Used as a medicine in Russia for ischemic stroke and neurological indications; current Russian authorization details are unverified here. No FDA approval or EMA authorization was identified.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
Stroke research should not be generalized to everyday focus enhancement. Independent, well-controlled studies and clearer safety data are needed.
No news yet for this peptide.
Sharper focus and memory with less anxiety: 'calm focus'.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.